The antithrombin activity test measures how well a natural anticoagulant protein called antithrombin is working in your blood, helping doctors understand why someone might form clots too easily or, less often, why a blood thinner like heparin does not seem to be working as expected. This lab test is part of the broader coagulation testing family that includes PT/INR and aPTT, but it looks at a different piece of the clotting puzzle: the body’s own braking system rather than the accelerator. This guide explains what antithrombin does, why a doctor might order the test, how to read reference ranges, what high or low results can mean, and when clotting symptoms deserve prompt medical attention.
What antithrombin activity measures
Antithrombin is a small protein made mainly by the liver that circulates constantly in the bloodstream. Its job is to inhibit, or slow down, several proteins involved in blood clotting, especially thrombin and a clotting factor called factor Xa. Clotting itself is a normal and necessary process that stops bleeding after an injury, but the body needs a counterbalance so clots do not form inappropriately inside intact blood vessels. Antithrombin acts as part of that counterbalance, alongside proteins C and S.
The antithrombin activity test specifically checks whether the antithrombin present in a blood sample functions correctly, rather than simply counting how many antithrombin molecules exist. A related test, antithrombin antigen, measures the amount of the protein without confirming it works properly. Ordering both together can help distinguish between a true shortage of antithrombin and a normal amount of antithrombin that does not function well.
How the test is performed
A phlebotomist draws blood from a vein, usually from the arm, into a tube containing an anticoagulant called sodium citrate, which keeps the sample from clotting before testing. The laboratory spins the sample to separate the liquid plasma from blood cells, since this measurement is taken in plasma rather than whole blood. Most laboratories use a chromogenic assay, a method that adds factor Xa and a color-producing substrate to the plasma, then measures how much color develops. Because antithrombin blocks factor Xa, less color developing means more activity, and more color developing means less.
No special fasting or physical preparation is typically required before this blood draw. People taking heparin, warfarin, or newer direct factor Xa inhibitors such as rivaroxaban or apixaban should tell their clinician and the laboratory, since these medications can distort the result. Results usually take one to three days, depending on the laboratory.
Why doctors order an antithrombin activity test
Clinicians most often order this test after someone develops an unexplained blood clot, particularly a deep vein thrombosis in the leg or a pulmonary embolism in the lung, especially if the clot occurred at a young age, recurred, or ran in the family. Doctors also order it when investigating unexplained pregnancy loss, since clotting disorders can sometimes play a role, and when a patient on heparin therapy needs unusually high doses to reach a therapeutic effect, a situation clinicians call heparin resistance.
In hospital settings, clinicians may check this marker in critically ill patients with suspected disseminated intravascular coagulation (DIC), a serious condition in which clotting and bleeding systems become dangerously imbalanced throughout the body at the same time. Antithrombin levels tend to fall during DIC because the protein gets consumed faster than the liver can replace it, so tracking it can add useful information alongside other coagulation tests.
Common reasons for testing
Doctors typically request this test in a handful of recurring clinical situations rather than as a routine screening tool for the general population.
- A first blood clot occurring before age 50 without an obvious cause such as recent surgery or prolonged immobility
- Recurrent blood clots, or clots that run strongly in the family
- Clots forming in unusual locations, such as abdominal veins
- Suspected or confirmed heparin resistance during hospital treatment
- Evaluation for disseminated intravascular coagulation in critically ill patients, often alongside a broader panel that may include a total iron-binding capacity test when anemia or protein loss is also suspected
- Unexplained recurrent pregnancy loss, sometimes evaluated alongside other clotting factor tests
Understanding antithrombin activity reference ranges
Reference ranges can vary slightly between laboratories depending on the exact assay used, so the number printed on your lab report should always take priority over any general figure. That said, most adult reference ranges for antithrombin activity fall between about 80 percent and 130 percent of normal pooled plasma activity. Values below this range suggest reduced antithrombin function, while values above it are less common and usually carry less clinical significance on their own.
Newborns, especially those born prematurely, naturally have lower antithrombin activity that rises to adult levels over the first few months of life, so pediatric reference ranges differ from adult ones. The table below summarizes typical adult ranges and general interpretations, though your own clinician will always interpret your specific result in the context of your health history and other tests.
| Antithrombin activity result | General interpretation | Possible associated context |
|---|---|---|
| Above 130% | Higher than typical activity | Usually of limited clinical significance; occasionally seen with certain anticoagulant medications or inflammation |
| 80%–130% | Typical adult range | Considered within normal limits for most laboratories |
| 70%–79% | Mildly reduced | May reflect minor hereditary variation or mild acquired causes; often warrants repeat testing |
| 40%–70% | Moderately to significantly reduced | Range often seen with hereditary antithrombin deficiency or notable acquired deficiency (liver disease, heparin therapy, DIC) |
| Below 40% | Severely reduced | Uncommon; typically prompts urgent clinical evaluation, often in the setting of severe acute illness |
What high or low antithrombin activity results can indicate
A low antithrombin activity result is the more clinically significant finding and can arise from either hereditary or acquired causes. Hereditary antithrombin deficiency is a genetic condition caused by changes in the SERPINC1 gene, the gene that provides instructions for making antithrombin. People with this inherited condition are usually born with activity levels somewhere between 40 percent and 70 percent of normal and face a lifelong higher risk of forming blood clots, particularly deep vein thrombosis and pulmonary embolism, often starting in the teenage or young adult years.
Acquired deficiency is considerably more common than the hereditary form and can result from several different situations: heparin treatment itself, which speeds up the breakdown of antithrombin; liver disease, since the liver makes antithrombin and clinicians often check liver enzyme levels such as AST when investigating the underlying cause; nephrotic syndrome, a kidney condition that causes protein loss into the urine; disseminated intravascular coagulation; severe infections and inflammation; and certain chemotherapy medications. In most acquired cases, a low reading acts more as a marker of how sick someone is rather than a direct, isolated cause of clotting risk, though it may still contribute to that risk.
A high result is less common and generally carries less established clinical meaning. It can sometimes appear during treatment with direct factor Xa inhibitor medications such as rivaroxaban or apixaban, which can interfere with the chromogenic assay and produce a falsely elevated reading. Isolated high results without other symptoms typically do not require specific treatment, though your clinician may repeat testing or check for medication interference.
Heparin, antithrombin, and why the two are linked
Antithrombin and the blood thinner heparin work as a team. On its own, antithrombin inhibits thrombin and factor Xa at a fairly slow, modest pace. Heparin binds to antithrombin and changes its shape slightly, which speeds up its inhibitory action by roughly a thousand-fold. This is precisely why heparin can only work as an anticoagulant when enough functional antithrombin is present in the bloodstream; heparin essentially supercharges a mechanism antithrombin already has, rather than acting as an independent clot-blocker itself.
This relationship explains heparin resistance, a situation in which a patient needs unusually high heparin doses to reach an adequate anticoagulant effect. According to a 2024 literature review in The Journal of Extra-Corporeal Technology, heparin resistance during cardiac surgery can stem from several mechanisms, and antithrombin deficiency is one of the most frequently cited, alongside interference from a platelet protein called platelet factor 4 and faster-than-expected heparin clearance. When clinicians identify a low level as a contributor, options include giving additional heparin, administering fresh frozen plasma, or supplementing antithrombin directly with a concentrated product.
Latest scientific advances
Interest in antithrombin has grown recently in a few specific clinical areas, particularly heart surgery and severe trauma, and researchers are working to clarify exactly when supplementing antithrombin helps patients versus when it does not change outcomes.
One line of research looked at whether replacing antithrombin actually helps surgery patients. According to PubMed, a 2023 analysis published in Anesthesia and Analgesia reviewed years of data on antithrombin supplementation after heart surgery. In plain terms, patients with low levels after their operation did tend to have more complications, but when antithrombin was actually given to correct those low levels in randomized trials, it did not improve outcomes, and it was linked to a higher rate of kidney injury in some studies. For a reader, this means a low result after major surgery is best understood as a sign the body has been through a lot, similar to a fever indicating the body is fighting something, rather than a problem that automatically needs fixing by giving more antithrombin. The reliability here is reasonably strong, since it draws on multiple prospective and randomized studies rather than one small trial (DOI: 10.1213/ANE.0000000000006314).
A second area of research has focused on a newer, more specific cause of heparin resistance connected to a medication called andexanet alfa, which doctors use to reverse certain blood thinners during emergency bleeding. According to PubMed, a 2024 laboratory study explained the mechanism: andexanet alfa does not use up antithrombin, but instead grabs onto antithrombin already bound to heparin, pulling it out of action so heparin cannot work as intended. In everyday terms, patients who receive this reversal medication before urgent heart surgery may find their blood resists the anticoagulation needed for the heart-lung bypass machine, sometimes requiring very high heparin doses or extra antithrombin to overcome the effect. This research is still relatively new, based on laboratory and modeling work rather than large patient trials, so it is an emerging but plausible explanation rather than settled fact (DOI: 10.1101/2024.09.09.612152). A related 2025 rapid review in the Journal of Thrombosis and Haemostasis examined fourteen documented cases of this problem and found that giving antithrombin concentrate before the reversal medication’s effects fully developed appeared to help keep clotting times safer, though the authors noted that more structured research is still needed (DOI: 10.1016/j.jtha.2025.01.008).
A third study looked at antithrombin outside the surgical setting entirely, in patients with traumatic brain injury. According to PubMed, this research, published in Frontiers in Immunology, followed 49 patients with isolated head injuries and measured several blood clotting markers within hours of injury. In plain language, patients with lower levels shortly after their head injury were substantially more likely to have a poor long-term recovery six months later, and this marker turned out to be a stronger individual predictor of outcome than several other markers tested, including Glasgow Coma Scale scores measured at the bedside. This suggests antithrombin may reflect how the body’s clotting and inflammation systems respond to serious injury, though the researchers were clear this was a single-center study with a modest number of patients, so the reliability is moderate and would benefit from confirmation in larger, multi-center studies before changing clinical practice (DOI: 10.3389/fimmu.2022.981826).
When to see a doctor about clotting risk
Most people never need this test, and an isolated abnormal result rarely signals an emergency on its own. Certain symptoms of a blood clot warrant prompt medical evaluation, particularly if you or a close family member has a known history of a clotting disorder.
Seek same-day medical care for symptoms suggesting a deep vein thrombosis, which typically develops in the leg: new swelling, warmth, redness, or aching pain in one leg that appears without an obvious injury, especially on only one side. Seek emergency care immediately for symptoms suggesting a pulmonary embolism, which occurs when a clot travels to the lungs: sudden shortness of breath, sharp chest pain that worsens with breathing, a rapid heartbeat, or coughing up blood. Clinicians confirm these clots using imaging that visualizes blood vessels, such as computed tomography angiography for detecting vessel blockages, alongside blood tests. These symptoms need urgent attention whether or not you have ever been tested for antithrombin deficiency.
It is also reasonable to discuss testing with a clinician if you have experienced a clot before age 50 without a clear trigger, if two or more close relatives have had blood clots or a known inherited clotting disorder, or if you are planning a pregnancy and have a strong family history of clotting problems, since some clotting risks matter more during pregnancy and the weeks after delivery.
Factors that can affect your results
Several situations beyond an underlying clotting disorder can shift an antithrombin activity result, so clinicians usually interpret a single value in the context of the full clinical picture rather than in isolation.
- Heparin therapy, which can temporarily lower the measured value into the abnormal range during treatment
- Direct oral factor Xa inhibitors such as rivaroxaban, apixaban, and edoxaban, which can falsely raise the measured value and mask a true deficiency
- Pregnancy, which causes modest, usually temporary shifts in several clotting-related proteins
- Acute illness, major surgery, or trauma, all of which can transiently lower antithrombin as the protein is consumed faster than usual
- Liver disease, since the liver is where antithrombin is produced
- Estrogen-containing medications, including some hormonal contraceptives
- Sample handling issues, such as improper mixing or delayed processing, which laboratories try to minimize with strict collection protocols
Because of these many influences, a single low or high result is often repeated after any acute illness has resolved and while the person is off interfering medications, whenever that is medically safe, before drawing firm conclusions about a hereditary deficiency.
How antithrombin testing fits with other coagulation tests
This test is rarely ordered or interpreted entirely on its own. Clinicians typically combine it with a broader thrombophilia panel that looks for various inherited or acquired tendencies toward excessive clotting, commonly including protein C activity and protein S activity, two other natural anticoagulant proteins with roles similar to antithrombin; factor V Leiden testing, which looks for a common genetic variant that makes a clotting factor resistant to being shut off; and a lupus anticoagulant panel, which screens for antibodies that can promote clotting.
Antithrombin activity also differs meaningfully from the more familiar international normalized ratio used to monitor warfarin therapy, since that ratio reflects how long blood takes to clot overall, while this result reflects the strength of one specific natural brake on that clotting process. Similarly, aPTT (activated partial thromboplastin time) measures a broader portion of the clotting cascade and commonly monitors unfractionated heparin therapy, whereas this test specifically explains why that same heparin might or might not be working well in a given patient, much as clinicians reviewing an ECG check for a normal sinus rhythm alongside coagulation results before cardiac procedures.
Living with hereditary antithrombin deficiency
People diagnosed with this inherited condition are not automatically destined to develop a blood clot, but roughly half will experience at least one clotting event during their lifetime, usually after adolescence. Management typically centers on avoiding additional risk factors when possible, discussing hormonal medication choices such as estrogen-containing contraceptives with a clinician, and using preventive blood thinners during genuinely high-risk periods, such as major surgery, prolonged hospitalization, long-haul travel, or pregnancy and the weeks following delivery, when clinicians may also monitor blood pressure more closely given the added strain pregnancy places on the vascular system.
Clinicians generally do not recommend lifelong blood-thinning medication for someone who has never had a clot, since the medications carry their own bleeding risks that must be weighed against a clotting risk that, while elevated, is not a certainty. After a first clot, many recommend longer-term or even indefinite anticoagulation instead, since the risk of a second clot in this population is meaningfully higher than average. These decisions are individualized and typically involve a hematologist experienced in inherited clotting disorders.
Frequently asked questions
Do I need to fast before an antithrombin activity test? No special fasting is required. You can generally eat and drink normally beforehand unless your clinician orders other tests at the same visit that do require fasting.
Can antithrombin activity be low without any hereditary condition? Yes. Acquired low antithrombin activity from liver disease, heparin therapy, severe infection, or another acute illness is considerably more common than hereditary deficiency, and it typically improves once the underlying illness resolves or the interfering medication is stopped.
What is the difference between antithrombin activity and antithrombin antigen? Antithrombin activity measures how well the antithrombin protein functions, while antithrombin antigen measures how much of the protein is present, regardless of whether it works properly. Ordering both can help clarify whether a deficiency involves too little protein, a normal amount of poorly functioning protein, or both.
Is antithrombin activity testing done during pregnancy? It can be, particularly for people with a personal or family history of blood clots or recurrent pregnancy loss. Pregnancy itself can cause modest shifts in several clotting factors, so results are interpreted with that context in mind, and testing decisions are made individually with an obstetric or hematology clinician.
Can antithrombin activity testing diagnose disseminated intravascular coagulation by itself? No single test diagnoses DIC. Clinicians evaluating for this condition typically look at antithrombin activity alongside platelet count, fibrinogen, D-dimer, and prothrombin time, since DIC produces a recognizable pattern across several tests rather than one isolated abnormal value.
If my antithrombin activity is slightly low, does that mean I will definitely get a blood clot? Not necessarily. A mildly low result, especially a first result during acute illness or heparin treatment, does not guarantee a clot will occur. Clinicians usually consider the degree of reduction, whether it persists after repeat testing under stable conditions, family history, and other risk factors together before estimating overall risk.
Glossary
| Term | Definition |
|---|---|
| Antithrombin | A protein made by the liver that naturally slows down blood clotting by inhibiting thrombin and factor Xa. |
| Thrombin | An enzyme at the center of the clotting process that converts fibrinogen into fibrin, the mesh that forms a clot. |
| Factor Xa | A clotting protein that helps activate thrombin; several modern blood thinners work by blocking this factor directly. |
| Chromogenic assay | A laboratory method that uses a color-changing chemical reaction to measure how active a protein, like antithrombin, is in a sample. |
| Heparin resistance | A situation in which a patient needs an unusually high dose of heparin to achieve the expected anticoagulant effect. |
| Disseminated intravascular coagulation (DIC) | A serious condition, usually triggered by severe illness or injury, in which clotting and bleeding processes become dangerously imbalanced throughout the body. |
| SERPINC1 gene | The gene that carries instructions for making the antithrombin protein; mutations here cause hereditary antithrombin deficiency. |
| Thrombophilia | A general term for any inherited or acquired condition that raises the tendency to form blood clots. |
| Deep vein thrombosis (DVT) | A blood clot that forms in a deep vein, most often in the leg, which can cause swelling and pain. |
| Pulmonary embolism (PE) | A blockage in a lung artery caused by a clot that traveled there from elsewhere in the body, usually the legs. |
Further reading
- Read about the international normalized ratio used to monitor warfarin and other blood thinners.
- Review the platelet distribution width test and how it fits into a complete blood count.
- See the shortness of breath guide covering causes, tests, and when to seek urgent care, since sudden breathlessness can signal a pulmonary embolism.
- Check the DHEA hormone test guide and how supplements can shift its results.
- Learn about the deep tendon reflex exam used as part of a neurological assessment, relevant background for the traumatic brain injury research discussed above.
Sources
- MedlinePlus Genetics, National Library of Medicine, National Institutes of Health — Hereditary antithrombin deficiency, reviewed 2013 — medlineplus.gov
- Mayo Clinic Laboratories — ATTF: Overview, Antithrombin Activity, Plasma, Test Catalog — mayocliniclabs.com
- U.S. Food and Drug Administration — Drugs@FDA record for Thrombate III (antithrombin III human), an FDA-approved antithrombin concentrate — accessdata.fda.gov
- Ranucci M, Baryshnikova E, Pistuddi V, Di Dedda U — The Rise and Fall of Antithrombin Supplementation in Cardiac Surgery — Anesthesia and Analgesia, 2023 — doi.org/10.1213/ANE.0000000000006314
- Butt SP, Kakar V, Kumar A, et al. — Heparin resistance management during cardiac surgery: a literature review and future directions — The Journal of Extra-Corporeal Technology, 2024 — doi.org/10.1051/ject/2024015
- Chabata CV, Yu H, Ke L, et al. — Andexanet alfa-associated heparin resistance in cardiac surgery: mechanism and perspectives — bioRxiv preprint, 2024 — doi.org/10.1101/2024.09.09.612152
- Mishima Y, Townsend G, Clifton SC, et al. — Andexanet-induced heparin resistance in cardiac surgery: a rapid review of case reports and series — Journal of Thrombosis and Haemostasis, 2025 — doi.org/10.1016/j.jtha.2025.01.008
- Takahashi M, Wada T, Nakae R, et al. — Antithrombin activity levels for predicting long-term outcomes in the early phase of isolated traumatic brain injury — Frontiers in Immunology, 2022 — doi.org/10.3389/fimmu.2022.981826
Antithrombin activity is one piece of a much larger coagulation picture, and understanding it often makes more sense alongside related tests such as PT/INR, aPTT, and a platelet count, especially if you already have lab results in hand and are not sure what they mean together. BloodSense helps translate values like these into plain-language explanations so you can see how individual results relate to one another and prepare more focused questions for your clinician, without replacing the medical guidance a doctor provides.
